Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia

Learn more about:
Related Clinical Trial
Correlating Protection Against Malaria With Serum Profiles Against Plasmodium Falciparum Antigen Repertoires Prevalence of Chronic Kidney Disease (CKD) and Risk Factors in Sub-Saharan Africa S. Japonicum and Pregnancy Outcomes Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions L-praziquantel Orodispersible Tablets (L-PZQ ODT) in Schistosoma Infected Children The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda Praziquantel in Children Under Age 4 Schistosoma Haematobium Infections and Praziquantel Antioxidant Supplements in the Reversal of Schistosomal Peri-portal Fibrosis Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults Single-sex Female Controlled Human Schistosomiasis Mansoni Infection An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni) Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal Praziquantel-Pharmacokinetic Study Schistosomiasis in Women of Reproductive Age in Burkina Faso: Implications for Control Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia Schistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control Programmes Using Community-Based Volunteers to Reach Non-Enrolled School Aged Children Through Community-Directed Treatment of Schistosomiasis in School-Aged Children in Rural Northern Ghana Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study Schistosomiasis in Senegal Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST) Childhood Schistosomiasis: a Novel Strategy Extending the Benefits/Reach of Antihelminthic Treatment Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis Arachidonic Acid Treatment Against Schistosomiasis Infection in Children Detection of Schistosomiasis CAA in Travellers After High-risk Water Contact Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis Health Benefits of Repeated Treatment in Pediatric Schistosomiasis Seropositivity and Adverse Birth Events in Migrants From Bilharzia-endemic Areas Women and Children as the Focus for Control of Schistosomiasis Infections in the Irrigations Area of Burkina Faso

Brief Title

Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia

Official Title

Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia

Brief Summary

      The objectives of this study is:

        -  to establish the coverage rate of weekly iron supplementation in children in
           intervention schools over a period of nine months

        -  document any side effects of weeekly iron supplementation among children in intervention
           schools over a period of nine months asses the feasibility of incorporating the weekly
           iron supplementation programme into the normal school activity in intervention schools
           determine the extent of acceptability and support for the iron supplementation programme
           by staff at the health centre nearest to the intervention schools

        -  compare the praziquantel efficacy and schistosomiasis reinfection in children in
           intervention schools with that of children in control schools following the introduction
           of weekely iron supplementation over a period of nine months

        -  determine the impact of weekly iron supplementation on haemoglobin levels of children in
           intervention schools and compare with children in control schools over a period of nine
           months
    

Detailed Description

      Iron deficiency anaemia is a common denominator for both schistosomiasis and soil transmitted
      helminths. Iron deficiency appears to affect the immune response against schistosomes and
      intestinal helminths. It therefore follows that correcting the iron deficiency anaemia will
      improve the efficacy of anthelminthics such as praziquantel (against schistosomiasis) and
      albendazol (against soil transmitted helminths) and ability of the host immune system to
      resist reinfection with schistosomes and soil transmitted helminths.

      The aim of this study is to identify factors necessary for a successful weekly iron
      supplementation programme in schistosomiasis and soil transmitted helminths control
      programmes. In addition impact of weekly iron supplementation programme n haemoglobin levels,
      efficacy of praziquantel, and schistosomiasis re-infection will be studied.
    


Study Type

Interventional


Primary Outcome

Urine samples examined for schistsoma haematobium at month 0, 3. 6 and 9

Secondary Outcome

 Any side effects to iron supplementation, measured every week for the first foru weeks after treatment start. Mesured on:

Condition

Schistosomiasis

Intervention

ferrous sulphate (drug)


Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

480

Start Date

September 2005

Completion Date

April 2006


Eligibility Criteria

        Inclusion Criteria:all schoolchildren, in grade 2 and 3, at four selected schools -

        Exclusion Criteria:

        -
      

Gender

All

Ages

9 Years - 15 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Victor Mwanakasale, Ph.d.,M.Sc., , 

Location Countries

Zambia

Location Countries

Zambia

Administrative Informations


NCT ID

NCT00276224

Organization ID

SRP-ZM-VM-04



Study Sponsor

DBL -Institute for Health Research and Development


Study Sponsor

Victor Mwanakasale, Ph.d.,M.Sc., Principal Investigator, Tropical Disease Research Centre, Ndola, Zambia


Verification Date

October 2007